Friday, December 11, 2020

Important policy changes for Google Account storage

                                                                                                                                                                                              
New inactive and over quota storage policies
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌
Dear Google User,
We are writing to let you know that we recently announced new storage policies for Google Accounts using Gmail, Google Drive (including Google Docs, Sheets, Slides, Drawings, Forms, and Jamboard files) and/or Google Photos that bring us in line with industry practices. Since you have previously used one or more of these products in your Google Account storage, we wanted to tell you about the new policies well before they go into effect on June 1, 2021. Below is a summary of the new policies. Please reference our Help Center article for a complete list of what's changing.
Summary of the new policies (effective June 1, 2021):
If you're inactive for 2 years (24 months) in Gmail, Drive or Photos, we may delete the content in the product(s) in which you're inactive. Google One members who are within their storage quota and in good-standing will not be impacted by this new inactive policy.
If you exceed your storage limit for 2 years, we may delete your content across Gmail, Drive and Photos.
What this means for you:
You won't be impacted by these changes unless you've been inactive or over your storage limit for 2 years. As this policy goes into effect June 1, 2021, the earliest it would be enforced is June 1, 2023.
After June 1, 2021, if you are either inactive or over your storage limit, we will send you email reminders and notifications in advance and prior to deleting any content.
Even if you are either inactive or over your storage limit for one or more of these services and content is deleted, you will still be able to sign in.
Note: The inactivity and over quota storage policies will apply only to consumer users of Google services. Google Workspace, G Suite for Education and G Suite for Nonprofits policies are not changing at this time, and admins should look to the Admin Help center for storage policies related to their subscriptions.
Learn more about how to keep your account active
To learn more about how to remain active with these products, visit this Help Center page.
The Inactive Account Manager can help you manage specific content and notify a trusted contact if you stop using your Google Account for a certain period of time (between 3-18 months). Note: the new 2 year inactive policy will apply regardless of your Inactive Account Manager settings. You can learn more about these changes and ways to manage your or a loved one's account in our Help Center.
Learn how to manage your storage
Learn more about the over quota policy and what counts against storage quota.
You can use the free storage manager in the Google One app and on the web to see how you're using your Google Account storage, and free up space across Gmail, Google Drive, and Google Photos.
Your Google Team

Tuesday, February 25, 2020

Learn more about our updated Terms of Service

Google
Updating Our Terms of Service
We're improving our Terms of Service and making them easier for you to understand. The changes will take effect on March 31, 2020, and they won't impact the way you use Google services.
For more details, we've provided a summary of the key changes and Frequently Asked Questions. At a glance, here's what this update means for you:
Improved readability: While our Terms remain a legal document, we've done our best to make them easier to understand, including by adding links to useful information and providing definitions.
Better communication: We've clearly explained when we'll make changes to our services (like adding or removing a feature) and when we'll restrict or end a user's access. And we'll do more to notify you when a change negatively impacts your experience on our services.
Adding Google Chrome, Google Chrome OS and Google Drive to the Terms: Our improved Terms now cover Google Chrome, Google Chrome OS, and Google Drive, which also have service-specific terms and policies to help you understand what's unique to those services.
No changes to our Privacy Policy: We're not making any changes to the Google Privacy Policy and we haven't made any changes to the way we treat your information. As a reminder, you can always visit your Google Account to review your privacy settings and manage how your data is used.
If you're the guardian of a child under the age required to manage their own Google Account and you use Family Link to manage their use of Google services, please take some time to discuss these changes with them.
And of course, if you don't agree to our new Terms and what we can expect from each other as you use our services, you can find more information about your options in our Frequently Asked Questions.
Thank you for using Google's services.
Your Google team

Sunday, May 13, 2018

Improvements to our Privacy Policy and Privacy Controls

Google
Updating Our Privacy Policy
This month, we're updating our Privacy Policy to make it easier for you to understand what information we collect and why we collect it. We've also taken steps to improve our Privacy Checkup and other controls we provide to safeguard your data and protect your privacy.
Nothing is changing about your current settings or how your information is processed. Rather, we've improved the way we describe our practices and how we explain the options you have to update, manage, export, and delete your data.
We're making these updates as new data protection regulations come into effect in the European Union, and we're taking the opportunity to make improvements for Google users around the world.
Making our Privacy Policy easier to understand
Simpler structure & clearer language
We've improved the navigation and organization of the policy to make it easier to find what you're looking for. We've also explained our practices in more detail and with clearer language.
New descriptive videos & illustrations
Often a visual description is easier to understand than text alone, so we've added short videos and illustrations throughout the policy.
Embedded privacy controls
We've made it easier to jump to key settings directly from the policy, helping you make choices about your privacy.
The revised policy is available here and will take effect on May 25, 2018.
Improving your privacy controls
Within the past year, we updated My Activity so that you can better access and manage the data in your Google Account. We also launched a redesigned Dashboard, which allows you to easily see an overview of products you're using and your data associated with them.
This month, we've updated our Privacy Checkup with new illustrations and examples to help you make more informed choices about your key privacy controls. And since we understand that your preferences may change over time, the new Privacy Checkup enables you to sign up for regular reminders to check your privacy settings.
To learn more about these and other controls to manage your privacy, visit your Google Account.

Saturday, November 16, 2013

Drug Trial for Chagas Disease Produces Mixed Results

Medindia Health News
Medindia largest health website in india. // via fulltextrssfeed.com 
Retargeting on Facebook?

Get more sales and conversions with Facebook retargeting. Try it free for 14 days. Set up takes just minutes!
From our sponsors
Drug Trial for Chagas Disease Produces Mixed Results
Nov 16th 2013, 11:09


Less than 1% of patients living with Chagas disease currently receive treatment. The new findings fill a long-standing knowledge gap, providing evidence that will help to inform public health policies and help to increase access to treatment now, as well as shaping the direction of future research for new Chagas therapies.

E1224 is a new antifungal compound discovered and manufactured by the Japanese pharmaceutical company Eisai that is being developed as a treatment for Chagas disease with support from the Wellcome Trust. The Phase 2 double-blind, randomized, controlled trial evaluated the safety and efficacy of E1224 at three different dose regimens and was the first study to collect comprehensive clinical data on the current approach to treatment, benznidazole. Both treatments were compared to a placebo control.

A total of 231 adult patients with chronic indeterminate (showing no symptoms) Chagas disease were treated for a maximum of 60 days and evaluated at treatment completion and at several different time points up to a 12-month follow-up assessment. The study took place at two sites (Cochabamba and Tarija) in Bolivia, which have the world's highest incidence of Chagas disease.

At end of treatment, E1224 was found to be safe and efficacious in clearing the Chagas parasite in patients when compared to placebo and to benznidazole. Few patients receiving the highest dose stopped treatment with E1224 due to side effects, less than in the benznidazole group. However, at 12 months after treatment, less than one third of patients treated with E1224 continued to maintain parasite clearance compared with over 80% of patients treated with benznidazole, demonstrating relatively low sustained eradication rates with E1224 in this study.

"In this prospective placebo-controlled study, these mixed results actually have provided very important scientific evidence on new drug development for Chagas disease, which has long been ignored," said Dr Isabela Ribeiro, Head of the Chagas Clinical Programme at DNDi, and the E1224 Project Leader. "We now have clear safety and efficacy data on two compounds that will be very useful in guiding future Chagas disease drug research efforts."

Although E1224 was found to be ineffective as a single-treatment agent (monotherapy), it holds promise for use in combination with existing drugs, since it showed strong positive activity during treatment, with a third of patients having a sustained treatment response at the higher dose. E1224 will no longer be tested as monotherapy for Chagas disease, but DNDi and Eisai are exploring the possibility of testing E1224 in combination therapy with benznidazole

"Eisai remains committed towards the elimination of neglected tropical diseases and hopes to continue collaboration with DNDi in future studies that could determine the role that E1224 may play in the treatment of chronic indeterminate Chagas disease and provide newer and better treatment options for patients suffering from this disease," stated Dr Frederick P. Duncanson, Senior Director of Chief Innovation Officer Group at Eisai Inc., and the E1224 Project Leader at Eisai.

In addition to evaluating E1224, the study was the first to compare the clearance of Chagas parasites (Trypanosoma cruzi) with benznidazole treatment versus placebo in adults with chronic indeterminate Chagas disease. Benznidazole had a rapid and sustained effect, with significant drop in parasite counts after just one week of treatment. Some patients experienced adverse events, mostly nausea, skin reactions, and muscle and nerve pain. Since benznidazole treatment is typically 60 days long and undesirable side effects are common, shorter courses of the drug may be safer yet still effective. Based on these study findings, DNDi will investigate shorter-course treatments with benznidazole.

The study was the first Phase 2 clinical trial conducted in Bolivia, exemplifying the strengthening and sustaining of research capacity in a resource-limited, developing-country setting. A total of 97% of the enrolled patients completed follow-up at 12 months post-treatment, with only 7 of the 231 patients being lost to follow-up. Important Chagas patient data were collected on pharmacokinetics and pharmacodynamics, characterization of the parasite population before and after treatment, and candidate biological markers for evaluation of treatment response.

"The completion of this drug trial was a success story for Chagas patients, doctors, and researchers in Bolivia, demonstrating that excellent clinical testing can be carried out in endemic countries," said Dr Faustino Torrico of Universidad Mayor de San Simon in Cochabamba, Bolivia, and one of the lead investigators. "The data generated were of high quality, and our clinical sites and research teams gained valuable experience and are ready to perform future studies."

"Chagas disease is one of world's most neglected illnesses, and millions of patients continue to be ignored and many needlessly die from the lack of treatment access and options," said Dr Bernard P�coul, Executive Director of DNDi. "We have to take advantage of these important study results to scale up treatment access now, while we maintain momentum in developing safer, more effective, life-saving new treatments for Chagas patients around the world."

Source: Eurekalert

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

Colombia's Cali Home to a Very Unique 'Hotel'

Medindia Health News
Medindia largest health website in india. // via fulltextrssfeed.com 
Retargeting on Facebook?

Get more sales and conversions with Facebook retargeting. Try it free for 14 days. Set up takes just minutes!
From our sponsors
Colombia's Cali Home to a Very Unique 'Hotel'
Nov 16th 2013, 11:09


Working in a posh neighborhood of Cali, Colombia's third largest city, the 55-year-old Diaz pampers her clients, from the time they get off the plane throughout their stay at her clinic.

She looks over them during their post-surgical convalescence, treating them to special diets and massages. A bilingual nurse who speaks English helps out.

"The most important thing is love, affection. We are here to give a little of it to people who need it while they have left their family, their husband, their children, who are also suffering for them on the other side of the world," she told AFP. Many patients get depressed after surgery, she says.

Her calling started off in a personal way. Her daughter, living in the United States, came home for a tummy tuck with liposuction. Mom's tender loving care prompted her to suggest Diaz open up the beauty-oriented hotel.

It now has a dozen rooms, with prices ranging from $55 to $68 a day.

Business is good because Colombia has a tradition as being a good place for plastic surgery. It is the third busiest in the sector in Latin America, after Brazil and Mexico, and ranked 11th in the world.

Every year more than 200,000 plastic surgery operations are carried out in Colombia, or 3.3 percent of the world total, according to the International Society of Aesthetic Plastic Surgery (ISAPS).

One client, a Spanish male nurse aged 39 who asked not to be named, also came for abdominal surgery. He was prompted to do so by a female Colombian friend who talked up Cali. Besides the affordable price, he said, "it is the quality that counts."

Technological Innovation

For Miriam Alvarado, a 53-year-old from Puerto Rico, the decision to undergo surgery in Colombia came after her sister and sister-in-law went under the knife here.

In a matter of two weeks, it was all set: the trip and the operation -- one on her chin, and liposuction.

And oh, what a bargain it was. At home it would have cost her $14,000, but in Cali, it cost less than $4,000.

And the medical facilities seem better to her. "In Puerto Rico there are all kinds of surgeons but the post-op treatment is not as advanced as it is here," Alvarado said.

Another convert is Peter McCabe, a US businessman who lives in Colombia. He had work done on his face, despite warnings from his family not to go through with it.

They said "if you are going to do it, please do it at home," he said.

But after they saw his new face on Skype, many changed their minds and some plan to jump on a plane to Colombia for a bit of tweaking of their own.

But all this is not without risk.

Between three and five percent of patients are not satisfied with the results of their surgery, and that figure jumps to 12 percent for nose work, said Lina Triana, a surgeon in Cali and secretary of ISAPS. She says there are non-qualified people out there offering operations.

But the good ones are in fact really good, she insisted.

"Now it is our colleagues in Europe and the United States who must learn here how to sculpt beautiful bodies," Triana said.

Technological innovation is one of the strong suits of Colombian doctors, who hold a convention every year to show off their techniques.

For instance, Alfonso Riascos unveiled a special method for carrying out a "facial rejuvenation" without leaving telltale scars near the ears, as is often the case.

"I began more or less five years ago with selected patients and now I have 400," he said proudly. A third are foreigners. His trademark is a small and discreet five-centimeter (two-inch) scar on the scalp.

Hotel owner Alba does not expect business to slow down any time soon.

"We have had family groups, with the father, the mother and three children. One of the daughters brought her husband. They love to have company," Diaz said.

Source: AFP

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

Democrats Vote for US House Bill Cutting 'Obamacare'

Medindia Health News
Medindia largest health website in india. // via fulltextrssfeed.com 
Microsoft Excel 2010 Training Course

Beginner / Intermediate self-paced online course of Microsoft's spreadsheet application. Enroll for just $99.
From our sponsors
Democrats Vote for US House Bill Cutting 'Obamacare'
Nov 16th 2013, 11:09


But the broad bipartisan vote, even if just a political messaging bill, marked a blow to a president under heavy fire for his largely discredited pledge that all Americans who liked their health plans could keep them.

Added to that is the flawed rollout of the HealthCare.gov website through which millions of Americans are expected to sign up for insurance.

"Today, the House made a big, bipartisan statement about the need to make things right," Speaker John Boehner said in a statement.

"The Keep Your Health Plan Act represents an important step toward providing relief to those who have lost their plans and face much higher premiums, but the real solution is to scrap the president's fundamentally-flawed health care law" altogether, he added.

The controversial measure, which passed 261-157, addresses what has emerged as a major sticking point in the law known as "Obamacare" -- millions being notified that the insurance plans they purchased on the open individual market are being cancelled, apparently because the coverage is sub-standard.

The bill is different from the "fix" proposed by Obama Thursday, which would allow insurers to keep offering such coverage only to those consumers who already are enrolled in the insurance in question.

New consumers would be required to obtain insurance that meets the law's standards. The House measure, however, opens the sub-standard plans to anyone.

Democrat Nick Rahall broke ranks and voted for the bill, saying Americans were disgusted with the "very bad, rotten" rollout of Obamacare.

House and Senate Democrats are offering several fixes of their own, suggesting the unity among Obama and members of his party has begun to fray.

But Rahall downplayed any tension between Obama and congressional members of his party.

"I don't think he should see it as a growing rift between the two but rather as a need to call everybody together to fix the problem," Rahall told reporters.

Senator Mary Landrieu, also a Democrat, is proposing a "permanent" solution that allows consumers with sub-standard plans to keep them for as long as they wish.

But she envisioned that under her bill, those Americans would gradually shift to the more comprehensive plans, whereas the House bill introduced by Republican Fred Upton would essentially kill Obamacare.

House Democratic leader Nancy Pelosi said Upton's bill was a "Trojan horse" that would "essentially pull the plug on the Affordable Care Act."

Source: AFP

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions